Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;32(9):1091-1098.
doi: 10.1097/MEG.0000000000001731.

Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment

Lorenzo Bertani  1 , Maria Gloria Mumolo  2 , Gherardo Tapete  1 , Eleonora Albano  1 , Giovanni Baiano Svizzero  1 , Federico Zanzi  1 , Linda Ceccarelli  2 , Massimo Bellini  1 , Santino Marchi  1 , Francesco Costa  2
Affiliations

Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment

Lorenzo Bertani et al. Eur J Gastroenterol Hepatol. 2020 Sep.

Abstract

Fecal calprotectin has been widely studied in inflammatory bowel disease (IBD) under clinical and therapeutic settings. It showed a good correlation with clinical, endoscopic, and histologic findings. For these reasons, fecal calprotectin is currently one of the most useful tools in IBD care, both in diagnosis and in clinical management. The development of biologic drugs allowed a deeper control of disease, which sometimes reaches histological healing; this is associated with a reduced risk of relapses and complications. The management of IBD treatment is currently carried out with a treat-to-target approach, and mucosal healing is considered at present to be the optimal therapeutic target, but the future is going through histologic remission. Fecal calprotectin is probably the best marker of mucosal healing, but it is correlated also with histologic remission: moreover, it has been recently studied as a possible therapeutic target in the CALM study. We carried out a comprehensive literature review in order to evaluate the role of fecal calprotectin at present and in the future in the management of IBD therapies.

PubMed Disclaimer

References

    1. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem. 1983; 134:1–6
    1. Rodrigo L. Fecal calprotectin. Rev Esp Enferm Dig. 2007; 99:683–688
    1. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012; 18:1894–1899
    1. Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, et al. From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol. 2018; 24:3681–3694
    1. Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004; 13:279–284

LinkOut - more resources